Take a trial of Europe to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -27.0%

FINANCIAL BRIEF: For the six months ended 30 June 2014, MDxHealth SA revenues totaled $4.8M. Net loss totaled to $8M. Results are not comparable due to currency change. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: €5.00 (+23.81% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (€) (€) (€) (€) (€) (€)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for MDxHealth SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 0 2

Named Brokers and Analysts
ING FM Luke Poloniecki , KBC Securities Jan Dekerpel , Petercam (Historical) Roderick Verhelst ,

MDxHealth SA is a Belgium-based company that develops and commercializes epigenetic assays and service testing for cancer assessment and the personalized treatment of patients. The Company’s offerings are structured into two divisions: Clinical Molecular Diagnostics (ClinicalMDx) solutions, providing physicians with tests which aid in the identification and treatment of their cancer patients, and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions, collaborating with pharmaceutical companies on the development of companion diagnostics, biomarker discovery, and clinical trial testing. Its ClinicalMDx solutions include four different product types: ConfirmMDx, InformMDx, RecurMDx and PredictMDx. MDxHealth‘s PharmacoMDx services, provided to both existing collaborators and on contracted services basis, focus on the identification and development of epigenetic biomarkers and molecular tests into companion diagnostics. The Company has one wholly owned subsidiary, MDxHealth Inc.

Directors: Jan Groen (CEO) , Joseph Sollee (EVP) 48, Christopher Thibodeau (EVP) 42, Wim van Criekinge (CSO) , Francis Ota (VFN) 60, Miriam Reyes (VOP) , Joseph Bigley (VPR) , Ming-Chou Lee (VPR) , Edward Erickson (NEC) 68, Rudi Marien (NED) 69, Rudi Pauwels (IND) 52, R. Devenyns (NID) 48, Mark Myslinski (NID) 58,

No. of Employees: 84 No. of Shareholders: 0


Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 34,251,303
Free Float 30.5m (89.1%)
ISIN BE0003844611
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Euronext - Brussels
Eligible for an ISA? a SIPP?

MDXH Share Price Performance MDXH Quote
€4.02
-0.0  -0.5%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest MDXH News Announcements (delayed)

Upcoming MDXH Events
Thursday 2nd October, 2014
MDxHealth SA at CF&B Large & Midcap Event
Friday 29th May, 2015 (estimate)
MDxHealth SA Annual Shareholders Meeting

Recent ↓
Tuesday 9th September, 2014
MDxHealth SA at Rodman & Renshaw Global Investment Conference
Thursday 21st August, 2014
Q2 2014 MDxHealth SA Earnings Release
Friday 30th May, 2014
MDxHealth SA Annual Shareholders Meeting
Friday 30th May, 2014
MDxHealth SA Extraordinary Shareholders Meeting
Thursday 20th March, 2014
MDxHealth SA at KBC Healthcare Conference
Tuesday 4th March, 2014
MDxHealth SA at Sachs Associates EUROPEAN LIFE SCIENCE CEO FORUM PARTNERING & INVESTING IN BIOTECH & PHARMA INDUSTRY Conference
Monday 24th February, 2014 (estimate)
Q4 2013 MDxHealth SA Earnings Release
Monday 13th January, 2014
MDxHealth SA at JPMorgan Healthcare Conference
Thursday 14th November, 2013
MDxHealth SA at KBC Benelux Biotech & Healthcare Seminar
Wednesday 6th November, 2013
Q3 2013 MDxHealth SA Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy MDXH

Access MDXH Analytics Now!

FREE TRIAL or TAKE THE TOUR